Introduction
============

Pterygium is a common fibrovascular proliferative disease exhibiting prominent vascularity that originates from the limbal conjunctiva and grows toward the cornea.[@b1-opth-12-1539] Its etiology is not completely understood, but some possible risk factors include older age, decreasing geographical latitude, and male sex.[@b2-opth-12-1539] Treatment options for pterygium range from conservative management with artificial tears and topical steroids to multiple methods of surgical excision when the visual axis is threatened.

Intraocular pressure (IOP) remains the only modifiable risk factor for the development and progression of glaucoma.[@b3-opth-12-1539] After cataract surgery, IOP may increase during the postoperative period. The elevation in IOP is undesirable, particularly if the patient has a history of glaucoma.[@b4-opth-12-1539],[@b5-opth-12-1539] Similarly, early elevation in IOP after pterygium surgery, which is not fully explained by steroid response alone, has been noted in previous studies and at our institution.[@b6-opth-12-1539] While Kuryan et al, identified a significant elevation in IOP after pterygium surgery, they did not find any identifiable risk factors.[@b6-opth-12-1539] Therefore, in this study, we aimed to identify the potential risk factors for the elevation in IOP beyond what have been previously reported, namely, race, given our high number of Hispanic patients, as well as different methods of use of postoperative steroids. Although the elevation in IOP has been found to be short-term and is controllable with pressure-lowering medications, it can remain significantly elevated, which makes it difficult to control during the postoperative period for many patients.[@b7-opth-12-1539]--[@b9-opth-12-1539]

Materials and methods
=====================

Patient selection and data collection
-------------------------------------

This is a single center retrospective cohort study that evaluated all patient charts with a pterygium removal surgery between April 10, 2014 and June 8, 2017 at a tertiary care center, Boston Medical Center, Boston, MA, USA. A single examiner performed chart review after approval by the Boston University Medical Center Institutional Review Board (H-35567). Given the retrospective nature of this study, patient consent was waived as this study does not pose greater than minimal risk to study subjects. All patient data was deidentified, coded, and limited to research personnel for patient confidentiality. The following inclusion criteria were applied: age ≥18 years, at least one postoperative follow-up visit at Boston Medical Center, and one documented preoperative IOP measurement within normal limits (10--22 mmHg). Patients with undiagnosed ocular hypertension as defined by the elevated IOP of the contralateral eye after surgery were excluded from the study. A total of 240 surgeries from 214 patients were reviewed for inclusion in this study.

Data collected from patient charts included date of surgery, date of follow-up visits, IOP of surgical and nonsurgical eyes, cup-to-disc (C/D) ratio of surgical and nonsurgical eyes, frequency of use of postoperative steroid drops, length of steroid use, past ocular history, race, age, and sex. Race was determined by the patient's self-identified race as documented in the patient's electronic medical record (EMR). Haitian-Creole ethnicity was stratified into the African race for this study.[@b10-opth-12-1539] In addition, an assumption that the patient's self-identified race was their sole race was also made.

Intraocular pressure measurements
---------------------------------

Clinically significant postoperative elevation of IOP was defined as a Goldmann or Tonopen reading of \>22 mmHg or an increase of IOP by ≥10 mmHg from baseline IOP. Eyes with clinically significant postoperative elevation in IOP were grouped in the "Ocular Hypertension" group, and all other eyes were grouped in the "No Ocular Hypertension" group. In this study, IOP measurements recorded by the technicians were used unless a clinically significant IOP was recorded, in which case a resident or attending clinician's measurement value was used. Patients who had elevated IOP of the nonsurgical eye with an equal or greater value than that of the surgical eye were defined as the undiagnosed ocular hypertension and therefore were excluded from statistical analysis.

Postoperative care
------------------

Six different primary surgeons performed the pterygium removal surgery of all 240 eyes using fibrin glue with a conjunctival autograft or an amniotic membrane graft. Postoperatively, all patients were administered with topical antibiotic, steroid drops, and anesthetic. These medications were adjusted as clinically necessary. In patients with significantly elevated IOP, topical glaucoma medications were started in accordance with the clinical need. For all patients post operative steroid regimen consisted of either high frequency (6 times per day) or low frequency (4 times per day). Additional steroid treatment included subconjunctival dexamethasone injection, neomycin-polymyxin-dexame-thasone 3.5 mg/g--10,000 unit/g--0.1% ointment, or both. Patients were scheduled for postoperative follow-up visits on day 1, week 1, month 1, and month 3 after surgery. Some patients required additional or extended follow-up visits when clinically necessary, and some patients missed their follow-up visits.

Statistical analysis
--------------------

In case of patients who required pterygium surgery on both eyes, the eye with the higher postoperative IOP was included for the statistical analysis. No patients required two pterygium surgeries for recurrence during the timeframe of this study. In addition, the data of patients who did not identify their race were not included in the statistical analysis for race and for multivariate logistic regression analysis. Statistics were calculated using the Statistical Package for the Social Sciences 24.0 for Macintosh (SPSS, Chicago, IL, USA). Continuous data were expressed as mean ± SD and compared using Student's *t*-test. Categorical data was expressed as the number for each category and compared using the chi square test (*χ*^2^). All categorical risk factors were subjected to multivariate logistic regression analysis. All graphs were prepared using GraphPad Prism 7 software (GraphPad, La Jolla, CA, USA). Tests required a significance level of *p* \< 0.05.

Results
=======

Patient characteristics
-----------------------

A total of 240 pterygium surgeries were reviewed. Twenty-six patients required pterygium surgeries on both eyes, in which case only the postoperative eye with higher IOP was analyzed. Data of two patients were removed from analysis because of the postoperative elevation in IOP in the nonsurgical eye, which we defined as ocular hypertension secondary to steroid response. Thus, a total of 212 surgeries were included in the analysis. Of these, 46 (21.7%) patients had glaucoma-related diagnoses consisting of 38 (17.9%) patients with suspected glaucoma, 3 (1.4%) primary patients with open-angle glaucoma (POAG), 2 (0.9%) patients with pseudoexfoliation syndrome, 2 (0.9%) patients with suspected closed-angle glaucoma status-post laser peripheral iridotomy, and 1 (0.4%) patient with normal tension glaucoma.

Overall, patient characteristics included a mean age of 50.38 ± 14.59 years, majority being males 52.8% (112/212), baseline IOP of 14.34 ± 2.88 mmHg, and C/D ratio of 0.333 ± 0.153 ([Table 1](#t1-opth-12-1539){ref-type="table"}). A total of 48 (22.6%) patients were included in the "Ocular Hypertension" group. This group had an average age of 48.67 ± 15.60 years, baseline IOP of 14.83 ± 2.86 mmHg, and C/D ratio of 0.357 ± 0.173. There was no statistically significant difference between these values in the "Ocular Hypertension" group compared with the 164 patients in the "No Ocular Hypertension" group, which showed an average age of 50.89 ± 14.30 years (*p* = 0.355), baseline IOP of 14.20 ± 2.88 mmHg (*p* = 0.177), and C/D ratio of 0.326 ± 0.147 (*p* = 0.242). Compared to the "No Ocular Hypertension" group, in the "Ocular Hypertension" group, there was a slight but insignificant higher score for male sex (50.6% (83/164) vs 60.4% (29/48), *p* = 0.231), preexisting glaucoma-related diagnoses (19.5% (32/164) vs 29.2% (14/48), *p* = 0.154), and high frequency of use of postoperative steroid drops (23.9% (39/164) vs 29.2% (14/48), *p* = 0.489).

Patients' self-identified races were Caucasian (21 \[10.1%\]), African (55 \[26.4%\]), Hispanic (114 \[54.8%\]), Asian (17 \[8.2%\]), and Arabic (1 \[0.5%\]) ([Table 2](#t2-opth-12-1539){ref-type="table"}). Incidence rates of developing elevated IOP differed significantly between Caucasians and non-Caucasians (1/21 \[4.8%\] vs 45/187 \[24.1%\], *p* = 0.043). This was not true for other races, that is, African (11/46, 23.9%) vs non-African (35/162, 21.6%, *p* = 0.659), Hispanic (30/114, 26.3%) vs non-Hispanic (16/94, 17.0%, *p* = 0.107), or Asian (4/17, 23.5%) vs non-Asians (42/191, 22.0%, *p* = 0.883). Compared to Caucasians, Hispanic race had a significantly different incidence rate (*p* = 0.031), which was not seen in African or Asian races (*p* = 0.103, 0.063).

Postoperative IOPs
------------------

When comparing the baseline vs postoperative day 1 IOP values ([Figure 1](#f1-opth-12-1539){ref-type="fig"}), we found a statistically significant increase among all the studied races. Average IOP increased from 14.6 ± 3.1 mmHg to 16.9 ± 4.3 mmHg in Africans (*p* \< 0.01), from 14.3 ± 2.8 mmHg to 17.6 ± 6.0 mmHg in Asians (*p* = 0.03), from 14.4 ± 2.5 mmHg to 15.9 ± 3.3 mmHg in Caucasians (*p* = 0.03), and from 14.3 ± 2.9 mmHg to 18.0 ± 4.8 mmHg in Hispanics (*p* \< 0.01). A statistically significant increase was also found in case of African and Hispanic race between baseline vs postoperative week 1 IOP values with averages of 17.3 ± 4.1 mmHg (*p* \< 0.01) and 17.8 ± 5.7 mmHg (*p* \< 0.01), respectively.

Among the 48 patients with postoperative elevated IOP, patients first developed clinically significant elevated IOP on an average of 9.42 ± 16.20 days postsurgery. Of these 48 patients, 29 (60.4%) patients had elevated IOP identified on postoperative day 1, 11 (22.9%) patients on postoperative week 1 (between 6 and 15 days), 7 (14.6%) patients on postoperative month 1 (between 22 and 44 days), and 1 (2.1%) patient on postoperative month 3 (83 days) ([Figure 2](#f2-opth-12-1539){ref-type="fig"}). [Figure 3](#f3-opth-12-1539){ref-type="fig"} shows the Kaplan--Meier survival curves for the time to the elevation of IOP by race. The probability of elevation of IOP at postoperative day 1 was 10.91% for Africans, 23.53% for Asians, 0% for Caucasians, and 15.79% for Hispanics. At week 1 (7 days) postoperative follow-up visit, the probabilities were 10.91% for Africans, 23.53% for Asians, to 3.70% for Caucasians, and 17.62% for Hispanics. At month 1 (31 days) postoperative follow-up visit, the probabilities were found to be 16.61% for Africans, 23.53% for Asians, 5.00% for Caucasians, and 23.68% for Hispanics. Probabilities of increased IOP were unchanged for Caucasians and Asians at 3 months' follow-up visit (92 days), but increased to 34.78% for Africans and 28.69% for Hispanics.

Postoperative subconjunctival injection or steroid ointment
-----------------------------------------------------------

In addition to topical prednisolone acetate 1% drops, all patients were treated with either perioperative subconjunctival injection of dexamethasone ("Subconjunctival Injection" group), topical neomycin-polymyxin-dexamethasone ointment ("Ointment" group), or both injection and ointment ("Both" group). Twelve patients were in the "Subconjunctival Injection" group and 7 out of 12 (58.33%) developed "Ocular Hypertension". This is compared to 25 out of 105 (23.81%) patients in the "Ointment" group and 17 out of 108 (15.74%) treated with both ([Table 3](#t3-opth-12-1539){ref-type="table"}). Using the "Both" group as the reference category, a statistically significant increase in percentage of patients developing "Ocular Hypertension" occurred in patients treated with only subconjunctival injection (*p* = 0.001). We did not find any difference between the "Ointment" and "Both" groups (*p* = 0.223).

Multivariate analysis
---------------------

In univariate analysis, Hispanic race was associated with increased incidence of "Ocular Hypertension" during the postoperative period (*p* = 0.031) ([Table 2](#t2-opth-12-1539){ref-type="table"}). In multivariate analysis, Hispanic race (OR = 9.845, 95% confidence interval \[CI\] = 1.157--83.741) was also associated with an increased risk of postoperative ocular hypertension (*p* = 0.036) ([Table 4](#t4-opth-12-1539){ref-type="table"}). African (OR = 6.361, 95% CI = 0.694--58.329) and Asian (OR = 8.976, 95% CI = 0.802--100.461) races were not found to be a significant risk factor in univariate ([Table 2](#t2-opth-12-1539){ref-type="table"}) or multivariate analysis (*p* = 0.102, 0.075) ([Table 4](#t4-opth-12-1539){ref-type="table"}). The "Subconjunctival Injection" group carried a significantly higher risk of development of ocular hypertension in univariate (*p* = 0.001) ([Table 3](#t3-opth-12-1539){ref-type="table"}) and multivariate analysis (OR = 6.627, 95% CI = 1.615--27.189, *p* = 0.009) ([Table 4](#t4-opth-12-1539){ref-type="table"}). Male sex also had higher rates of elevated IOP (OR = 1.241, 95% CI = 0.602--2.560) but was not significant (*p* = 0.559). In addition, no significant risks were found with a positive history of glaucoma (OR = 1.614, 95% CI = 0.725--3.593, *p* = 0.241) or with higher frequency of use of topical prednisolone acetate 1% drops (OR = 1.367, 95% CI = 0.542--3.448, *p* = 0.936).

Discussion
==========

Elevated IOP can be a serious complication after pterygium surgery. Our study evaluated the incidence and risk factors of elevated IOP postpterygium surgery after removing potential cases of undiagnosed ocular hypertension. We found that the percentage occurrence of postoperative ocular hypertension was high (22.64%), which is in line with the findings of other studies.[@b6-opth-12-1539],[@b11-opth-12-1539]

Topical steroids can induce ocular hypertension over the course of weeks.[@b12-opth-12-1539] According to Turalba et al, steroid-induced ocular hypertension was found to be at a rate of 2.97% after the surgery of photorefractive keratectomy.[@b13-opth-12-1539] Lorenz et al and Laurell et al reported a rate of 0--4.8% after cataract surgery.[@b14-opth-12-1539], [@b15-opth-12-1539] In this study, we found 21.28% rate of elevated IOP, which is much greater than that of other surgeries of anterior segment.[@b13-opth-12-1539]--[@b15-opth-12-1539] We believe that the majority of cases of elevated IOP in this study were due to pterygium surgery and not due to the steroid-induced ocular hypertension; this distinction, however, is difficult to ascertain with complete certainty. The majority (29/48) of elevated IOP cases were measured on postoperative day 1, sooner than the expected steroid response. Furthermore, we noticed that additional steroid use in the form of ointment and subconjunctival injection had fewer rates of elevated IOP ([Table 3](#t3-opth-12-1539){ref-type="table"}). Another potential source of error is the effect of early epithelial defect after pterygium surgery on Goldmann applanation tonometer measurements. The timing of the postoperative day 1 epithelial defect coincides with the elevation of IOP observed in this study.[@b16-opth-12-1539] However, this is likely not attributable to our study as irregular mires prompted the use of a Tonopen and would not explain the elevation in IOP in postoperative week 1 or month 1.

A possible explanation for the effects of pterygium surgery on IOP is its effects on corneal biomechanics. Pterygium leads to alterations of the anterior stroma, Bowman's membrane, and the epithelial layer of the cornea.[@b17-opth-12-1539] Two groups of researchers have reported that corneal hysteresis (CH), the cornea's ability to absorb pressure by bending, decreased after pterygium surgery compared to healthy controls during the first postoperative month.[@b18-opth-12-1539],[@b19-opth-12-1539] Low CH was also found to be associated with elevated IOP in patients with glaucoma and additionally correlated with visual field progression and optic disc surface compliance.[@b20-opth-12-1539],[@b21-opth-12-1539] It is possible that during the brief postoperative period, the effects of pterygium surgery prevented the cornea from bending and absorbing pressure exerted from aqueous humor, causing a transiently elevated IOP.

Another possible explanation for the elevated IOP after pterygium surgery is the effect of extraocular surgery on downstream drainage of aqueous humor. In the conventional trabecular meshwork drainage pathway, aqueous humor drains from Schlemm's canal to the aqueous vein and then into the episcleral and conjunctival veins. After removal of these downstream channels in pterygium surgery, it is possible that the residual episcleral and conjunctival veins were adjusting to the relative overloading of aqueous humor. This is similar to the elevation of IOP seen after extensive conjunctival removal in a previous case report.[@b22-opth-12-1539] In case of pterygium surgery, however, fewer conjunctivas were removed in this study, which may account for the transient instead of permanent elevation of IOP.

In this study, multivariate analysis identified Hispanic race as a strong risk factor for postoperative IOP spikes ([Table 3](#t3-opth-12-1539){ref-type="table"}). Genetic factors play a role in the pathogenesis of primary open-angle glaucoma, such as its determinants on IOP, C/D ratio, and central corneal thickness. A genome-wide association study has shown that these factors are highly heritable, vary according to race, and likely involve multiple polymorphisms.[@b23-opth-12-1539] Recently, a study performed on Hispanic population identified WNT7B as one locus, likely among many, that is associated with central corneal thickness.[@b24-opth-12-1539] Differences in genetic factors among racial groups may cause varying degree of responses after pterygium surgery.

In addition to Hispanic race, there is reason to suspect that other races have increased risk of elevated IOP. African race is a risk factor for the development of POAG, and our study showed a significant increase in IOP at week 1 postoperative visit ([Figure 1](#f1-opth-12-1539){ref-type="fig"}).[@b23-opth-12-1539],[@b25-opth-12-1539] Future studies with higher power may discover a significant risk for pterygium surgery-induced elevation of IOP in this group of patients.

The fact that patient demographics plays a significant role in the elevation of IOP after pterygium surgery raises interesting questions on its role in screening patients and their postoperative care. Our study shows that Hispanic race, and possibly African race, is a risk factor. While pterygium surgeries are relatively benign, we found that 22.64% of the patients develop elevated IOP; thus, these risk factors should be taken into consideration during screening. The importance of and potential need for more postoperative follow-up visits should be explained to patients with higher risk of suffering negative consequences of elevated IOP. While glaucoma-related diagnoses were not found to be a risk factor, preoperatively careful consideration for surgery and more regular follow-up visits is especially true for patients with glaucoma as elevated IOP can be even more problematic in this group of patients. The potential need for glaucoma management should also be discussed. Fourteen patients in this study required an addition of 1 glaucoma medication, 2 patients required an addition of 2 glaucoma medications, and 1 patient required an addition of 3 glaucoma medications. No patients required laser or surgery for management of IOP.

Differences between the rates of postoperative IOP elevation were also seen in certain types of steroid use. While all patients were prescribed prednisolone acetate 1% drops ophthalmic suspension, patients were additionally treated with either intraoperative subconjunctival dexamethasone injection and/or postoperative dexamethasone-containing ointment. Subconjunctival injection was associated with the highest rate of postoperative "Ocular Hypertension" at a rate of 58.33%, followed by the use of topical steroid ointment at a rate of 23.81%. Use of both methods combined had the lowest risk at a rate of 16.84%. Timing of steroid ointment use (immediately after the case or after postoperative day 1) did not significantly affect the development of "Ocular Hypertension". One explanation for this trend is that inflammation of the cornea contributes to the elevation in IOP. Use of topical loteprednol etabonate results in low aqueous humor concentration and decreases mean IOP by 1--2 mmHg after pterygium surgery relative to other corticosteroids.[@b26-opth-12-1539],[@b27-opth-12-1539] Loteprednol etabonate concentrations are also the highest in the cornea.[@b23-opth-12-1539] Topical steroid preparations might be able to treat inflammation better at this site than that of periocular preparations and a combination of these two might be synergistically useful in decreasing corneal inflammation.

Our study is also of interest because of our unique patient population. The National Institutes of Health (NIH) fiscal report documented that 8.4% of the domestic enrollment in NIH-funded clinical research were of Hispanic race in 2012, which came down from a rate of 8.6% in 2011.[@b28-opth-12-1539] While reviews found mixed results of Hispanic population as a risk factor for POAG, we were clearly able to define an association between Hispanic race and ocular hypertension after pterygium surgery given our large Hispanic population.[@b23-opth-12-1539]

This study had some limitations, which include the inherent biases in retrospective studies, including a nonrepresentative sample size and nonblinded chart reviews, among others. Furthermore, the primary objective of this study was to evaluate Hispanic race as a risk factor for the development of ocular hypertension, which accounted for 59.6% of the entire patient population at Boston Medical Center undergoing pterygium surgery. Thus, the power of this study was too low to significantly evaluate other demographic factors such as African or Asian race, which accounted for only 20.4 and 8.1%, respectively. Many follow-up visits were also missed by patients. While this was accounted for with censored times in the Kaplan--Meier survival curve ([Figure 3](#f3-opth-12-1539){ref-type="fig"}), other tables and figures likely underrepresent the number of cases in the "Ocular Hypertension" group. In addition, slight variations in surgical approach could also be a confounding factor. As previously stated, the power of this study is an additional limitation. A larger sample size might help to identify additional risk factors, and future studies should attempt to identify these risk factors into power calculations. Finally, given the retrospective nature of this study, a nonstandardized protocol of IOP measurement introduced additional biases. Multiple technicians and residents measured the IOP in addition to the use of both Goldmann Aplannation Tonometery and Tonopen. We believe that these methods do not detract from our results. Albeit Tonopen provides slightly overestimated readings. Previous studies found a nonsignificant difference between Goldmann Aplannation Tonometery and Tonopen measurements.[@b29-opth-12-1539],[@b30-opth-12-1539]

Conclusion
==========

Ocular hypertension after pterygium surgery is a common complication, and Hispanic race is a risk factor. It is possible that patients will require glaucoma medications after surgery to control their IOP, and Hispanic patients should be provided diligent preoperative screening and postoperative follow-up visits to prevent complications of prolonged elevated IOP. In addition, we found that the use of topical steroid ointments was associated with lower rates of ocular hypertension than that of steroid drops.

While other races were not found to be a significant risk factor in multivariate analysis, the original design of this study was to evaluate Hispanic race. It is likely that other races, such as African and Asian, are also risk factors for the development of ocular hypertension as was seen in univariate analysis. Future studies should include a larger population to observe additional risk factors. Patient age, baseline IOP, history of glaucoma-related diagnoses, C/D ratio, and frequency of use of topical steroid drops were not found to impact risk of developing ocular hypertension than that of a steroid injection.
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![Postoperative lOP compared to baseline by race. Only postoperative day 1 and week 1 were included as more follow-up visits were missed starting at month 1. Paired *t*-tests showed a significant difference in lOP from baseline at postoperative day 1 for all races. Postoperative week 1 was significantly elevated from baseline for African and Hispanic races only.\
**Abbreviation:** IOP, intraocular pressure.](opth-12-1539Fig1){#f1-opth-12-1539}

![Time of first recorded elevated lOP. Percent of when all patients first developed elevated lOP. The majority of cases in the "Ocular Hypertension" group were first found to have elevated lOP was at their day 1 postoperative appointment (60.4%).\
**Abbreviation:** IOP, intraocular pressure.](opth-12-1539Fig2){#f2-opth-12-1539}

![Kaplan--Meier survival curve for time to development of elevated lOP between African, Asian, Caucasian, and Hispanic races. Time was limited to 100 days as the last patient developed elevated lOP at 3 month postoperative appointment. Table shows the percent survival for each race at day 1, week 1, month 1, and month 3 postoperative visits.\
**Abbreviation:** IOP, intraocular pressure.](opth-12-1539Fig3){#f3-opth-12-1539}

###### 

Characteristics risk factors of patients for the development of elevated IOP

                                                    All cases (eyes) (N = 212)   Cases with ocular hypertension (N = 48)   Cases with no ocular hypertension (N = 164)   *p*-value
  ------------------------------------------------- ---------------------------- ----------------------------------------- --------------------------------------------- ---------------------------------------------------
  Age ± SD                                          50.38 ± 14.59                48.67 ± 15.60                             50.89 ± 14.30                                 0.355[a](#tfn1-opth-12-1539){ref-type="table-fn"}
  Sex, male (%)                                     112 (52.8)                   29 (60.4)                                 83 (50.6)                                     0.231[b](#tfn2-opth-12-1539){ref-type="table-fn"}
  History of glaucoma (%)                           46 (21.7)                    14 (29.2)                                 32 (19.5)                                     0.154[b](#tfn2-opth-12-1539){ref-type="table-fn"}
  Baseline IOP ± SD                                 14.34 ± 2.88                 14.83 ± 2.86                              14.20 ± 2.88                                  0.177[a](#tfn1-opth-12-1539){ref-type="table-fn"}
  C/D ratio ± SD                                    0.333 ± 0.153                0.357 ± 0.173                             0.326 ± 0.147                                 0.242[a](#tfn1-opth-12-1539){ref-type="table-fn"}
  Frequency of steroid used, higher frequency (%)   52 (24.5)                    13 (27.1)                                 39 (23.8)                                     0.489[b](#tfn2-opth-12-1539){ref-type="table-fn"}

**Notes:**

Student's *t*-test.

Chi square test. Age, baseline IOP, and C/D ratio were compared with Student's *t*-tests and showed no significant difference between ocular hypertension and no ocular hypertension groups. Sex, history of glaucoma related diagnoses, and frequency of prednisolone acetate 1% drops use where compared with Chi square test and no significant differences were found.

**Abbreviations:** IOP, intraocular pressure; C/D, cup-to-disc.

###### 

Racial risk factors for development of elevated IOP

  Race        All cases, N = 208 (%)   Cases with ocular hypertension, N = 46 (%)   Cases with no ocular hypertension, N = 162 (%)   *p*-value (race vs non-race)                         *p*-value (race vs Caucasian)
  ----------- ------------------------ -------------------------------------------- ------------------------------------------------ ---------------------------------------------------- ----------------------------------------------------
  Caucasian   21 (10.1)                1 (2.2)                                      20 (12.3)                                        0.043[\*](#tfn4-opth-12-1539){ref-type="table-fn"}   (Reference)
  African     55 (26.4)                11 (23.9)                                    44 (27.2)                                        0.659                                                0.103
  Hispanic    114 (54.8)               30 (65.2)                                    84 (51.9)                                        0.107                                                0.031[\*](#tfn4-opth-12-1539){ref-type="table-fn"}
  Asian       17 (8.2)                 4 (8.7)                                      13 (8.0)                                         0.883                                                0.089
  Arabic      1 (0.5)                  0 (0.0)                                      1 (0.6)                                          --                                                   --

**Notes:**

Results with an asterisk are statistically significant. Chi square tests were used to compare racial risk factors for development of elevated IOP. Statistical analysis showed that Caucasians have a decreased incidence of developing elevated IOP compared to African, Hispanic, Asian, and Arabic races combined (*p* = 0.043). When comparing individual races to Caucasian race, only Hispanic race was found to have a significantly increased risk of postoperative elevated IOP (*p* = 0.031).

**Abbreviation:** IOP, intraocular pressure.

###### 

Postoperative topical ointment vs subconjunctival steroid injection

  Type of steroid             Cases with ocular hypertension (%)   Cases with no ocular hypertension (%)   *p*-value
  --------------------------- ------------------------------------ --------------------------------------- ----------------------------------------------------
  Subconjunctival injection   7 (58.33)                            5 (41.67)                               0.001[\*](#tfn6-opth-12-1539){ref-type="table-fn"}
  Ointment                    25 (23.81)                           80 (76.19)                              0.223
  Both                        16 (16.84)                           79 (83.16)                              (Reference)

**Notes:**

Results with an asterisk are statistically significant. Subconjunctival injection of dexamethasone without topical ointment experienced a significantly increased incidence of ocular hypertension compared to use of both subconjunctival injection with neomycin-polymyxin B-dexamethasone ointment. Occurrences of ocular hypertension after treatment with topical ointment, subconjunctival injection, or both were compared with a chi square test using both steroid treatment options as the reference.

###### 

Multivariate adjusted odds ratio for the development of elevated IOP

                                      Number in ocular hypertension group/total   Incidence rate (%)   Multivariate adjusted odds ratio (95% CI)   *p*-value
  ----------------------------------- ------------------------------------------- -------------------- ------------------------------------------- ----------------------------------------------------
  Sex                                                                                                                                              
    Female                            18/99                                       18.18                (Reference)                                 --
    Male                              32/109                                      29.36                1.241 (0.602, 2.560)                        0.559
  History of glaucoma                                                                                                                              
    No                                38/163                                      23.31                (Reference)                                 --
    Yes                               12/45                                       26.67                1.614 (0.725, 3.593)                        0.241
  Frequency of steroid used                                                                                                                        
    Lower                             36/162                                      22.22                (Reference)                                 --
    Higher                            14/46                                       30.43                1.367 (0.542, 3.448)                        0.936
  Type of postoperative steroid use                                                                                                                
    Both                              17/93                                       18.28                (Reference)                                 --
    Topical ointment                  27/104                                      25.96                1.306 (0.568, 3.004)                        0.529
    Subconjunctival injection         6/11                                        54.54                6.627 (1.615, 27.189)                       0.009[\*](#tfn7-opth-12-1539){ref-type="table-fn"}
  Race                                                                                                                                             
    Caucasian                         1/21                                        4.76                 (Reference)                                 --
    African                           10/55                                       18.18                6.361 (0.694, 58.329)                       0.102
    Hispanic                          35/114                                      30.70                9.845 (1.157, 83.741)                       0.036[\*](#tfn7-opth-12-1539){ref-type="table-fn"}
    Asian                             4/17                                        23.53                8.976 (0.802, 100.461)                      0.075

**Notes:**

Results with an asterisk are statistically significant. When adjusted for sex, glaucoma history, frequency of steroid use, and ethnicity, use of subconjunctival injection was a significant risk factor for development of ocular hypertension (*p* = 0.005). In addition, Hispanics had a significantly increased risk of developing elevated IOP compared to Caucasians when adjusted for the above characteristics.
